Intralesional Administration of Large Doses of Human Leukocyte Interferon for the Treatment of Condylomata Acuminata

Geffen, Jeremy R.; Klein, Richard J.T.; Friedman‐Kien, Alvin E.

doi:10.1093/infdis/150.4.612

Cited by 56 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the past several years numerous studies using interferons either via intralesional, systemic, or topical routes have reported significant remission of genital human papilloma virus strains in variable proportions have already been reported [5,[9][10][11]. In a recent controlled study [5] we reported a 90% cure rate using leukocyte interferon-c~ cream (2• IU/g) in women (n=150) with no patient dropout.…”

Section: Discussionmentioning

confidence: 96%

Management of genital warts in women with human leukocyte interferon-? vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study

Syed

Khayyami²,

Kříž³

et al. 1995

J Mol Med

View full text Add to dashboard Cite

The purpose of this double-blind, placebo-controlled, comparative study was to evaluate the specific clinical efficacy and tolerance of human leukocyte interferon-alpha (2 x 10(6) IU/g) and podophyllotoxin 0.5% incorporated in a hydrophilic cream to cure genital warts. Preselected Asian women (n = 60) aged 18-40 years (mean 22.9), with a clinical and biopsy-confirmed diagnosis of genital warts, harboring 322 lesions (mean 5.36) were randomly assigned to three parallel groups to receive one of the two test drugs or placebo. Each patient received a precoded tube (40 g) containing either human leukocyte interferon-alpha, podophyllotoxin, or identically appearing placebo cream for 3 days' usage. In addition to written instructions, each subject was shown how to apply a minimal amount of trial medication on their lesions thrice daily for 3 consecutive days per week (maximum nine topical applications per week). Patients were examined on a weekly basis, and a cure was considered to be a biopsy-confirmed, total elimination of a lesion. Moreover, patients cured during the study period were spared further therapy, and were requested to return in 16 weeks to monitor for the occurrence of a relapse. The remaining patients' empty tubes were collected, and similarly precoded replacement tubes were given to continue the treatment; a total of 214 tubes were used. The study was scheduled for 16 weeks with 4 weeks of active treatment. Individuals were excluded from the study due to pregnancy, breast feeding, or the receiving of any type of antiviral therapy during the 4 weeks preceding enrollment.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussionmentioning

confidence: 96%

Management of genital warts in women with human leukocyte interferon-? vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study

Syed

Khayyami²,

Kříž³

et al. 1995

J Mol Med

View full text Add to dashboard Cite

show abstract

“…Studies have consistently demonstrated that treatment with intralesional IFN results in complete response rates greater than those associated with placebo. [186][187][188][189][190][191][192][193][194][195][196] Complete responses are defined as the disappearance of all clinically apparent lesions as well as prevention of new lesions during the given study period. Complete response rates for IFN treatment groups generally varied from 28% 191 to 100% 195 with 9 out of 16 studies surveyed reporting complete response rates between 40% and 60%.…”

Section: Interferonsmentioning

confidence: 99%

“…Complete response rates for IFN treatment groups generally varied from 28% 191 to 100% 195 with 9 out of 16 studies surveyed reporting complete response rates between 40% and 60%. 186,188,190,192,193,[196][197][198][199] Furthermore, warts treated with intralesional IFN may continue to resolve for days to weeks after the treatment. 187 While most intralesional IFN studies focus on IFNa treatments, IFNf3 has been studied and demonstrated results comparable to IFNa in most trials.…”

Section: Interferonsmentioning

confidence: 99%

Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy

et al. 2001

View full text Add to dashboard Cite

show abstract

“…A disadvantage to intralesional therapy is that it is directed only against visibly abnormal tissue and may leave subclinical infection untreated, as suggested by previous studies showing no response in uninjected warts. 19 In this issue, Friedman-Kien et al20 report results of a carefully designed study of intralesional natural leukocyte interferon. The 62% complete response rate observed in this refractory population is impressive.…”

Section: Interferon and Genitalmentioning

confidence: 99%

Interferon and Genital Warts: Much Potential, Modest Progress

Kirby¹

1988

JAMA

View full text Add to dashboard Cite

Intralesional Administration of Large Doses of Human Leukocyte Interferon for the Treatment of Condylomata Acuminata

Cited by 56 publications

References 5 publications

Management of genital warts in women with human leukocyte interferon-? vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study

Management of genital warts in women with human leukocyte interferon-? vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study

Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy

Interferon and Genital Warts: Much Potential, Modest Progress

Contact Info

Product

Resources

About